All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visit:
How will CAR T therapy for lymphoma be used in the future?
The Lymphoma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Gilles Salles, South Lyon University Hospital, Lyon, FR, discusses how CAR T therapy for lymphoma will be used in the future.
Gilles Salles explains that the use of CAR T cells will expand in the future, as the current market approval is for patients in the third line of therapy with primary mediastinal B‐cell lymphoma or diffuse large B‐cell lymphoma (DLBCL). He explains that he foresees an expansion in both the treatment of different histological subtypes and usage in earlier lines of treatments. He also discusses the ZUMA-7 and ZUMA-2 trials
How will CAR T therapy for lymphoma be used in the future?
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox